粪便细菌疗法
医学
大便失禁
临床试验
不利影响
粪便
移植
重症监护医学
内科学
外科
艰难梭菌
微生物学
生物
抗生素
作者
Xu-da Zhang,Q Y Chen,N Li,Hao Qin
出处
期刊:PubMed
[National Institutes of Health]
日期:2020-05-25
卷期号:23 (5): 509-515
被引量:1
标识
DOI:10.3760/cma.j.cn.441530-20200110-00015
摘要
Fecal microbiota transplant (FMT) has become an effective method for the treatment of recurrent C. difficile infection. In addition, it has shown certain effects in other diseases inside and outside the intestine. A large number of clinical trials have been carried out. However, there is still lack of uniform standard for strategies of FMT. In this paper, we discussed the current hot and controversial issues of FMT from the aspects of indication, donor screening, fecal suspension quality control, methodology, follow-up and efficacy judgment, treatment of adverse reaction and ethical supervision based on our team's clinical experience.菌群移植(FMT)已成为治疗复发性艰难梭菌感染的有效手段,除此之外,在其他肠道及肠外疾病的治疗尝试中也显示出一定的效果,大量临床试验相继开展。关于FMT具体方法尚缺乏统一标准。本文从FMT适应证、供体筛选、菌液质量控制、FMT方法学、随访及疗效判断、不良反应处理以及伦理监管等方面,针对FMT目前存在的热点与争议问题,并结合本团队临床治疗经验做综合介绍。.
科研通智能强力驱动
Strongly Powered by AbleSci AI